Skip to content
Live news Screener Coverage Pricing Docs REST API WebSocket API MCP server Company Use cases Blog Changelog Status Compare Contact
GMAB$43.85+3.85(+9.63%)Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer[7:00:00 AM ET]INCY$115.00-1.93(-1.65%)Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer[7:00:00 AM ET]NBTX$29.36+0.17(+0.58%)NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma[7:00:00 AM ET]ONC$377.63-4.64(-1.21%)BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026[4:15:00 AM ET]CMPX$0.77-0.03(-3.97%)Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026[4:15:00 AM ET]CELC$63.20-2.37(-3.61%)Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026[4:15:00 AM ET]ZYME$28.22-0.22(-0.77%)Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026[2:30:00 AM ET]IMTX$7.31-0.23(-3.05%)Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting[2:30:00 AM ET]LLY$1,279.00-27.69(-2.12%)Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026 Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its investigational folate receptor alpha (FRα) antibody-drug...[2:30:00 AM ET]LAWR$3.750.00(0.00%)Robot Consulting Announces Receipt of Nasdaq Delisting Determination and Request to Appeal such Determination Before a Hearings Panel[12:00:00 AM ET]

CV · NASDAQ

CapsoVision, Inc.

$6.99 +0.17 (+2.50%)

Company overview

CapsoVision is a medical-technology company that develops advanced capsule endoscopy systems, including the CapsoCam Plus and CapsoCam Colon, as well as AI-enabled imaging platforms for gastrointestinal diagnostics.

Sector
Healthcare
Industry
Medical - Specialties
Exchange
NASDAQ
Market cap
$372M
Employees
99
Headquarters
Saratoga, CA
CEO
Kang-Huai Wang
Listed
July 2, 2025
P/E
-6.66
Dividend yield
0.00%

Company financials

Revenue
$13.6M
Gross profit
$7M
Operating income
$5.6M
EBITDA
-$26.6M
Net income
-$27M
EPS
-$1.05
Total assets
$25.9M
Total debt
$788,000
Gross margin
51.67%
Net margin
-198.87%
Earnings yield
-15.02%

Revenue segmentation

By product (FY 2025)

No product segmentation.

By region (FY 2025)

Showing FY 2025

Price chart

5.526.116.717.307.89
CV 1D NASDAQ O6.78H7.18L6.73C6.97+0.17 (+2.50%)Vol69.66K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Source
Date
Type
Ticker Type Headline Source Published

Loading headlines…

FAQ

Questions about CapsoVision, Inc.

What does CapsoVision, Inc. do?
CapsoVision is a medical-technology company that develops advanced capsule endoscopy systems, including the CapsoCam Plus and CapsoCam Colon, as well as AI-enabled imaging platforms for gastrointestinal diagnostics.
What is CV's market cap?
CapsoVision, Inc. (CV) is a listed stock with a live quote. The latest market cap on this page is $372M.
Where is CapsoVision, Inc. headquartered?
CapsoVision, Inc. is headquartered in Saratoga, CA.
How do I get CV news from the API?
Call GET /v1/news?tickers=CV. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does CV news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for CV, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the CV price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included. If you don't subscribe, the account stays on Free.